QC
DNA icon

Quent Capital’s Ginkgo Bioworks DNA Stock Holding History

Quent Capital’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,009
Closed -$8.38K – 1559
2025
Q4 		$8.38K Hold
1,009
– – ﹤0.01% 1187
2025
Q3 		$14.7K Buy
+1,009
New +$12.1K ﹤0.01% 944
2025
Q2 		– Sell
-13
Closed -$74 – 542
2025
Q1 		$74 Sell
13
-138
-91% -$1.41K ﹤0.01% 1307
2024
Q4 		$1.48K Buy
+151
New +$1.29K ﹤0.01% 1203
2024
Q3 		– Sell
-125
Closed -$1.68K – 1362
2024
Q2 		$1.68K Buy
125
+93
+291% +$2.77K ﹤0.01% 1231
2024
Q1 		$1.48K Sell
32
-61
-66% -$3.16K ﹤0.01% 1262
2023
Q4 		$6.26K Buy
93
+53
+133% +$3.25K ﹤0.01% 1039
2023
Q3 		$2.92K Hold
40
– – ﹤0.01% 1140
2023
Q2 		$3K Hold
40
– – ﹤0.01% 1135
2023
Q1 		$2.15K Buy
40
+5
+14% +$317 ﹤0.01% 1156
2022
Q4 		$2.34K Buy
+35
New +$3.22K ﹤0.01% 1124

Other funds holding DNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.18B AUM 27.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Quent Capital's DNA Position: Q1 2026 in Review

Quent Capital sold out of Ginkgo Bioworks (DNA) in Q1 2026, closing a stake of 1,009 shares — an estimated $8.38K sold.

Quent Capital first reported a position in DNA in Q4 2022 and held it in 11 quarters. The position peaked at $14.7K in Q3 2025. 174 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

  • Quent Capital reported no remaining Ginkgo Bioworks position as of Q1 2026 after selling out during the quarter.
  • Quent Capital sold 1,009 Ginkgo Bioworks shares in Q1 2026, an estimated $8.38K.
  • Quent Capital first reported a position in Ginkgo Bioworks in Q4 2022 and held it in 11 quarters.
  • Quent Capital's Ginkgo Bioworks position peaked at $14.7K in Q3 2025.
  • 174 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on Quent Capital's 13F filing for Q1 2026, filed 28 Apr 2026.